Abstract
The 3-hydroxy-3-methylglutaryl coenzyme-A inhibitors or statins have been shown to reduce morbidity and mortality in patients with coronary artery disease or those at increased risk of coronary artery disease (Table). Consequently, statin therapy has become the cornerstone treatment in primary and secondary prevention of coronary artery disease for almost every patient category. However, the case for the use of statin therapy in the most advanced stage of the cardiovascular disease continuum, namely patients with chronic heart failure (CHF) has been disputed. Until recently, we simply lacked data …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
